INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update
INmune Bio reported Q1 2026 financial results with a net loss of $5.4 million, a significant improvement from the $9.7 million loss in the prior year period, driven largely by lower R&D expenses of $3.6 million compared to $7.6 million. The company achieved key regulatory milestones, completing a pre-submission package for CORDStrom™ with the UK MHRA and securing FDA alignment to advance XPro™ into an adaptive Phase 2b/3 registrational pathway for early Alzheimer's Disease.
Key figures
- Revenue
- 0
- Revenue Yoy
- -100%
- Net loss
- 5407000
- Ga expenses
- 2171000
- Rd expenses
- 3641000
- Shares outstanding
- 26600000
- Cash and equivalents
- 21358000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.